Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01581593
Recruitment Status : Unknown
Verified September 2013 by Kedrion S.p.A..
Recruitment status was:  Active, not recruiting
First Posted : April 20, 2012
Last Update Posted : September 13, 2013
Information provided by (Responsible Party):
Kedrion S.p.A.

April 16, 2012
April 20, 2012
September 13, 2013
November 2012
August 2014   (Final data collection date for primary outcome measure)
Incidence of acute, serious bacterial infections [ Time Frame: 13 months ]
The incidence of acute serious bacterial infections, e.g. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, visceral abscess.
Same as current
Complete list of historical versions of study NCT01581593 on Archive Site
  • Incidence of infections other than acute, serious bacterial infections [ Time Frame: 13 months ]
    The incidence of infections other than acute serious bacterial infections.
  • Evidence of change in daily activities due to infections [ Time Frame: 13 months ]
    • The number of days missed from work, school, kindergarten, day care, or days unable to perform normal daily activities due to infections.
    • Days of unscheduled physician visits and hospitalizations due to infection.
    • Days of therapeutic antibiotics.
  • IgG serum levels [ Time Frame: every month up to 13 months ]
    • IgG trough levels
    • Trough serum total IgG levels before each infusion of Kedrion IVIG 10% in all subjects and the interval between infusions will be recorded.
  • Incidence of adverse events [ Time Frame: 13 months ]
    • Overall incidence of adverse events that occur during or within 1 hour, 24 hours and 72 hours following an infusion of test product.
    • The proportion of adverse events considered by the investigator to be product related.
  • Incidence of decreased infusion rate due to adverse events [ Time Frame: 13 months ]
    The proportion and number of IVIG infusions for which the infusion rate was decreased due to adverse events.
Same as current
Not Provided
Not Provided
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).
The purpose of this study is to determine whether Kedrion IVIG 10% (an immunoglobulin solution) is effective in treating Primary Immunodeficiency (PID).

People with primary immunodeficiency diseases (PID) have a defective immune system and experience recurrent protozoal, bacterial, fungal and viral infections. Antibody deficiencies make up the largest group of PIDs.

The standard care for patients with PID is replacement immunoglobulin (a class of antibodies) solution. Prophylactic treatment with intravenous immunoglobulin (IVIG) solution has been shown to increase the time free from serious infection.

Kedrion IVIG 10% is a new preparation of an immunoglobulin G (IgG) solution. Kedrion IVIG 10% will be given by IV infusion to all study participants. The data collected will help determine whether Kedrion IVIG 10% is suitable for treating PID subjects.

Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Primary Immunodeficiency
  • Agammaglobulinemia
  • Hypogammaglobulinemia
  • Antibody Deficiency
Biological: Kedrion IVIG 10%
Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Duration - 12 months
Experimental: Kedrion IVIG 10%
Kedrion IVIG 10% treatment.
Intervention: Biological: Kedrion IVIG 10%
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
August 2014
August 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed clinical diagnosis of a Primary Immunodeficiency Disease
  • Male or female, ages 2 to 70 years
  • Received 300-900 mg/kg of a licensed IVIG therapy at 21 or 28 day intervals for at least 3 months prior to this study
  • 2 documented IgG trough levels of ≥ 5 g/L are obtained at two infusion cycles (21 or 28 days) within 12 months (one must be within 6 months) prior to study enrolment
  • Non-pregnant females of child-bearing potential who agree to use adequate birth control during the study
  • Subject is willing to comply with the protocol
  • Authorization to access personal health information.
  • Signed the informed consent form and a child assent form, if appropriate.
  • If currently participating in a clinical trial with another experimental IVIG may be enrolled if they have received stable IVIG therapy for at least 3 infusion cycles prior to receiving Kedrion IVIG 10% and all inclusion and exclusion criteria are satisfied
  • If currently participating in a trial of SCIG can be enrolled if they are switched to IVIG for three infusion cycles (21 or 28 days) prior to enrolment in this study

Exclusion Criteria:

  • Has secondary immunodeficiency.
  • Newly diagnosed and has not been treated with immunoglobulin or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency.
  • Has a history of repeated reactions or hypersensitivity to IVIG or other injectable forms of IgG.
  • Has a history of thrombotic events defined by at least 1 event in subject's lifetime.
  • Has IgA deficiency and is known to have antibodies to IgA.
  • Has received blood products other than human albumin or human immunoglobulin within 12 months prior to enrolment.
  • Has significant protein losing enteropathy, nephrotic syndrome or lymphangiectasia.
  • Has an acute infection as documented by culture or diagnostic imaging and/or a body temperature exceeding 38.5 °C (101.3 °F) within 7 days prior to screening
  • Has a known history or is positive at enrolment for human immunodeficiency virus (HIV) type 1 by NAT, hepatitis B virus (HBsAg and NAT), hepatitis C virus (by NAT), or hepatitis A virus (by NAT).
  • Has levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times of the upper limit of normal for the laboratory designated for the study.
  • Has an implanted venous access device
  • Has profound anemia or persistent severe neutropenia (≤ 1000 neutrophils per mm3)or lymphopenia of less than 500 cells per microliter.
  • Has a severe chronic condition such as renal failure (creatinine concentration > 2.0 times the upper limit of normal) with proteinuria, congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g. atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity, or any other condition that the investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
  • Has a history of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to enrolment.
  • Has history of epilepsy or multiple episodes of migraine (defined as at least one episode within 6 months of enrolment) not completely controlled by medication.
  • Is receiving steroids (oral or parenteral daily dose of ≥ 0.15 mg/kg/day of prednisone or equivalent) OR other immunosuppressive drugs or chemotherapy.
  • Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
  • Has participated in another clinical study within 3 weeks prior to study enrolment.
Sexes Eligible for Study: All
2 Years to 70 Years   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
Not Provided
Not Provided
Kedrion S.p.A.
Kedrion S.p.A.
Not Provided
Study Director: Mirella Calcinai, MD Kedrion SpA
Kedrion S.p.A.
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP